Cargando…

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma

Detalles Bibliográficos
Autores principales:	Zhu, You-Cai, Xu, Chun-Wei, Zhang, Qu-Xia, Wang, Wen-Xian, Lei, Lei, Zhuang, Wu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964938/ https://www.ncbi.nlm.nih.gov/pubmed/31809319 http://dx.doi.org/10.1097/CM9.0000000000000555

Ejemplares similares

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing
por: Zhu, You‐cai, et al.
Publicado: (2018)

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma
por: Zhu, You‐cai, et al.
Publicado: (2017)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
por: Sievers, Philipp, et al.
Publicado: (2021)

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion
por: Cai, Cun-Liang, et al.
Publicado: (2019)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma
por: Zhu, Yufei, et al.
Publicado: (2022)

The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition
por: Kahlon, Shira, et al.
Publicado: (2018)

Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
por: Chen, Hua-fei, et al.
Publicado: (2018)

Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement
por: Bedics, Gábor, et al.
Publicado: (2022)

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
por: Xu, Chun‐wei, et al.
Publicado: (2017)

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
por: Zhao, Zhi-Mei, et al.
Publicado: (2021)

Epigenetic profiling reveals a subset of pediatric-type glioneuronal tumors characterized by oncogenic gene fusions involving several targetable kinases
por: Sievers, Philipp, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age
por: Ke, Li, et al.
Publicado: (2018)

S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma
por: Xia, Yu, et al.
Publicado: (2022)

Genomic Profiling Reveals Synchronous Bilateral Lung Adenocarcinomas With Distinct Driver Alterations of EML4-ALK or TPM3-ROS1 Fusion: A Case Report
por: Tan, Benxu, et al.
Publicado: (2019)

Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases
por: Zheng, Jing, et al.
Publicado: (2020)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma
por: Yablecovitch, Doron, et al.
Publicado: (2022)

Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma
por: Chen, Jianing, et al.
Publicado: (2023)

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
por: Cortot, Alexis B., et al.
Publicado: (2014)

Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib
por: Ren, Xiaohui, et al.
Publicado: (2020)

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2020)

Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance
por: Lian, Zeng-Zhi, et al.
Publicado: (2016)

Community-acquired MRSA
por: Bloomfield, Sally F
Publicado: (2006)

Hepatoid adenocarcinoma of the lung accompanied with multiple systemic metastases
por: Chen, Jing-Xian, et al.
Publicado: (2021)

Toxic epidermal necrolysis induced by Lansoprazole: Pharmacologic considerations*
por: Gomes, Ciro Martins
Publicado: (2013)

An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma
por: Turnham, Rigney E, et al.
Publicado: (2019)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants
por: Park, Angela K.J., et al.
Publicado: (2015)

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
por: Zhao, Xue-Song, et al.
Publicado: (2019)

Acquired reactive perforating collagenosis
por: Wang, Chen, et al.
Publicado: (2020)

Dexamethasone in community-acquired pneumonia
por: Lee, Nelson, et al.
Publicado: (2011)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

Cutaneous Reaction Induced by Intramuscular Diclofenac Showing Epidermal Dysmaturation
por: Garcia-Malinis, Ana J, et al.
Publicado: (2022)

Naevus Spinofiliformis: A Novel Variant of Organoid Epidermal Naevus
por: Mendiratta, Vibhu, et al.
Publicado: (2022)

Oncogenic Effect of the Novel Fusion Gene VAPA-Rab31 in Lung Adenocarcinoma
por: Yoon, Daseul, et al.
Publicado: (2019)

Syndecan-3 and syndecan-4 are enriched in Schwann cell perinodal processes
por: Goutebroze, Laurence, et al.
Publicado: (2003)

Protein regulator of cytokinesis 1: a potential oncogenic driver
por: Li, Sijing, et al.
Publicado: (2023)

Clinical analysis of 23 patients pathologically diagnosed with primary and secondary pulmonary enteric adenocarcinoma
por: Gu, Lei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u805q0f0deujujok7bqqqjbu0m